Be The First To Find Out What Researchers Are Saying Over Epacadostat

Few patients (approximately 10-12) called and asked for a definition of the degree of toxicity. When the principle investigator was queried by the patient, he defined mild toxicity as ��inconvenient�� and moderate toxicity as ��a detriment to your quality of life.�� In this manner, we believe that our patient's perspectives were more accurately reflected. Weaknesses of our study involve those inherent with survey-based research, especially in asking patients about such ��hypothetical�� decisions. It is noteworthy that one of our observations was that a much greater proportion of patients https://www.selleckchem.com/products/MG132.html choose maintenance when asked in a ��yes-or-no�� fashion and when there was no evidence for an overall survival benefit when it was associated with mild or moderate toxicity than there were patients who identified https://www.selleck.cn/products/pfi-2.html of progression-free survival versus overall survival. Although we sent the survey to patients who were dealing with complications of myeloma, with many in the last year(s) of life, and asked emotional questions that required patients to reflect on mortality, we greatly exceeded our expectations with nearly a 70% response rate, which is similar to that described in the United Kingdom survey noted above. This suggests that patients with multiple myeloma are motivated to be involved in research and are invested in their care. Recently, our group proposed an approach to maintenance for multiple https://www.selleckchem.com/products/epacadostat-incb024360.html myeloma that generally would avoid those patients who have a very good partial response, a complete response, or a stringent complete response.[53, 54] It is our impression that such patients often experience a durable remission that can continue for 5, 10, or even 15 years or more; and, for these patients, maintenance would be less likely to produce a benefit, but they still would be subject to the not insignificant toxicity and financial burden of treatment. In personal communication with patients who contacted us with regard to the survey, patients had a wide range of perspectives and preferences. On one end of the spectrum was a patient of the principal investigator's, who stated that, without maintenance, she is currently able to ��think about�� her multiple myeloma once every 3 months and that maintenance would cause her to ��think about�� her myeloma daily. Consistent with this perspective, she chose not to fill out the survey, because it would have required her to ��think about�� her myeloma. On the other end of the spectrum, a gentleman who had had myeloma for over 3 years stated that he would tolerate ��ANY�� toxicity and ��ANY�� expense to gain a ��single day�� of life.